Ariad reports first Iclusig sales since U.S. relaunch

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) reported 1Q14 financial results on Wednesday, including $8 million in revenues for leukemia drug Iclusig ponatinib. The company recorded $4.7 million in 1Q14 Iclusig revenues in the U.S., where the biotech resumed marketing Iclusig in mid-January after FDA approved a REMS and a revised label limiting the drug's use. The company temporarily suspended U.S. marketing and distribution of Iclusig late last year at FDA's request due to the risk of arterial thrombotic events. EMA's CHMP made several recommendations on the use of Iclusig to help minimize the risk of occlusive vascular events but did not recommend the drug be removed from the European market (see BioCentury Extra, Dec. 20, 2013). ...